Brokers Offer Predictions for STOK FY2025 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Stoke Therapeutics in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan expects that the company will earn ($2.40) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.03) per share.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.05. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The company had revenue of $4.89 million during the quarter, compared to the consensus estimate of $3.46 million.

STOK has been the subject of several other reports. Chardan Capital started coverage on Stoke Therapeutics in a report on Friday, December 20th. They set a “buy” rating and a $24.00 price target for the company. Leerink Partnrs upgraded shares of Stoke Therapeutics to a “strong-buy” rating in a research note on Friday, October 11th. Leerink Partners initiated coverage on shares of Stoke Therapeutics in a research note on Monday, October 14th. They issued an “outperform” rating and a $18.00 price objective for the company. Needham & Company LLC reissued a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, January 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, January 8th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $21.29.

Stoke Therapeutics Price Performance

STOK opened at $9.80 on Wednesday. The stock has a fifty day moving average price of $11.40 and a 200 day moving average price of $12.87. Stoke Therapeutics has a 1 year low of $4.09 and a 1 year high of $17.58.

Hedge Funds Weigh In On Stoke Therapeutics

Several large investors have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company increased its position in shares of Stoke Therapeutics by 16.7% during the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock valued at $189,000 after purchasing an additional 1,994 shares during the period. Rhumbline Advisers raised its stake in shares of Stoke Therapeutics by 14.3% in the 2nd quarter. Rhumbline Advisers now owns 47,860 shares of the company’s stock valued at $647,000 after buying an additional 5,990 shares in the last quarter. Intech Investment Management LLC acquired a new position in shares of Stoke Therapeutics in the 3rd quarter valued at $160,000. Profund Advisors LLC acquired a new stake in shares of Stoke Therapeutics during the 2nd quarter valued at about $201,000. Finally, Mesirow Financial Investment Management Inc. bought a new stake in Stoke Therapeutics in the third quarter valued at about $192,000.

Insiders Place Their Bets

In related news, insider Barry Ticho sold 10,000 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $12.07, for a total transaction of $120,700.00. Following the transaction, the insider now owns 51,277 shares of the company’s stock, valued at approximately $618,913.39. The trade was a 16.32 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Edward M. Md Kaye sold 6,170 shares of the stock in a transaction on Friday, December 6th. The shares were sold at an average price of $12.78, for a total transaction of $78,852.60. Following the completion of the sale, the chief executive officer now directly owns 68,671 shares of the company’s stock, valued at approximately $877,615.38. This trade represents a 8.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 62,849 shares of company stock valued at $809,421 in the last three months. Company insiders own 11.30% of the company’s stock.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.